Bicycle Therapeutics reports Q3 2026 results, orphan drug status for nuzefatide in pancreatic cancerOct 29Quarterly updateBicycle Therapeutics Plc
Bicycle Therapeutics director Charles Swanton steps down from boardAug 20PeopleBicycle Therapeutics Plc
Bicycle Therapeutics reports Q2 2026 pipeline progress, cash into 2030Jul 30Quarterly updateBicycle Therapeutics Plc